Publications by authors named "Jan D Lunemann"

Claim this Profile
C
Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy-A pilot study.
Frauke Stascheit, Daniel Schulze, Sophie Lehnerer, Lea Gerischer, Maike Stein

J Autoimmun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polysialic acid restrains inflammatory monocyte maturation.
Ingredy Passos, Benjamin Peschke, Shrey Gandhi, Judith Derdelinckx, Louisa Müller-Miny

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.
Muriel Schraad, Mathias Mäurer, Anke Salmen, Tobias Ruck, Timo Uphaus

Ther Adv Neurol Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome.
Christian W Keller, Kerstin Stein, Andreu Vilaseca, Luisa M Villar, Gary Álvarez-Bravo

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral correlates of clinical response to thymectomy in myasthenia gravis.
Carla D F Sousa, Paula Terroba-Navajas, John Tzartos, Ivana D Orešković, Maja Pučić-Baković

J Autoimmun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund

Ann Clin Transl Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Polysialic acid restrains inflammatory monocyte maturation.
Ingredy Passos, Benjamin Peschke, Shrey Gandhi, Judith Derdelinckx, Louisa Müller-Miny

Front Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATG5 controls CD80 expression in B cells and shapes cognate CD4 T cell responses.
Ingredy Passos, Thomas Zobel, Christian Münz, Anneli Peters, Jan D Lünemann

Autophagy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoskeletal disruption-induced calcium dysregulation drives cell death in anti-IgLON5 disease.
Lisanne Korn, Júlia Csatári, Andreas Schulte-Mecklenbeck, Laura Vinnenberg, Nadine Ritter

Redox Biol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.
Javier Villacieros-Álvarez, Maria Sepulveda, Adrián Valls-Carbó, Nicolas Fissolo, Alessandro Dinoto

Neurol Neuroimmunol Neuroinflamm· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.
Tilman Schneider-Hohendorf, Christian Wünsch, Andreas Schulte-Mecklenbeck, Lisa Revie, Catarina Raposo

iScience· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.
Nicolás Fissolo, Sabine Schaedelin, Luisa M Villar, Jan D Lünemann, Jorge Correale

JAMA Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab.
Lisa Revie, Annika Jürjens, Maria Eveslage, Susan Trümpelmann, Valerie Teschner

Mult Scler· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.
Leonie Müller-Jensen, Nora Möhn, Thomas Skripuletz, Sophia Carl, Janin Thomas

J Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Géraldine Androdias, Jan D Lünemann, Elisabeth Maillart, Maria Pia Amato, Bertrand Audoin

Brain· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis Thymus.
Paula Terroba-Navajas, I-Na Lu, Isaak Quast, Michael Heming, Christian W Keller

Neurol Neuroimmunol Neuroinflamm· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis.
Johanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, Aleksandra Maleska Maceski, Lester Melie-Garcia

Neurol Neuroimmunol Neuroinflamm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes.
Paula Terroba-Navajas, Marianna Spatola, Omar Chuquisana, Bastien Joubert, Juna M de Vries

Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease.
Omar Chuquisana, Marianna Spatola, Alessandro Dinoto, María Sepúlveda, Sara Mariotto

Brain· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W Keller

Neurol Neuroimmunol Neuroinflamm· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving beyond immunoglobulin therapy for CIDP with efgartigimod.
Jan D Lünemann

Nat Rev Neurol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Javier Villacieros-Álvarez, Jan D Lunemann, Maria Sepulveda, Adrián Valls-Carbó, Alessandro Dinoto

Neurol Neuroimmunol Neuroinflamm· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV-specific T-cell immunity: relevance for multiple sclerosis.
Malina Behrens, Manuel Comabella, Jan D Lünemann

Front Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
Manuel Comabella, Harald Hegen, Luisa M Villar, Konrad Rejdak, Augusto Sao-Avilés

J Neurol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset.
Jan D Lünemann, Augusto Sao Avilés, Mar Tintoré, Luciana Midaglia, Nicolás Fissolo

Mult Scler· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis